Moleculin Biotech
MBRX
19 hedge funds and large institutions have $5.31M invested in Moleculin Biotech in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 4 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
198% more capital invested
Capital invested by funds: $1.78M → $5.31M (+$3.53M)
0% more ownership
Funds ownership: 0% → 0% (+0%)
5% less funds holding
Funds holding: 20 → 19 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.27M |
| 2 |
Renaissance Technologies
New York
|
+$818K |
| 3 |
BlackRock
New York
|
+$78.8K |
| 4 |
Morgan Stanley
New York
|
+$21.7K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$294K |
| 2 |
AC
Armistice Capital
New York
|
-$179K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$20K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$13.6K |
| 5 |
IWP
Icon Wealth Partners
Houston,
Texas
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Bank of America
Charlotte,
North Carolina
| – | -$20K | -11 | Closed |
|
|
IWP
27
Icon Wealth Partners
Houston,
Texas
| – | -$1K | -1 | Closed |
|
MBRX Hedge Fund Activity: Q2 2019 in Review
19 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2019, worth a combined $5.31M — up 198% from $1.78M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of MBRX and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $2.27M. The largest seller was CVI Holdings, exiting entirely with an estimated $294K sold.
- 19 institutional investors held Moleculin Biotech (MBRX) as of Q2 2019, down from 20 in Q1 2019.
- Funds reported $5.31M of Moleculin Biotech stock for Q2 2019, up 198% quarter-over-quarter.
- 3 funds opened new Moleculin Biotech positions in Q2 2019 and 4 closed out, a net change of -1 holder.
- The largest Moleculin Biotech buyer in Q2 2019 was Vanguard Group, an estimated $2.27M added.
- The largest Moleculin Biotech seller in Q2 2019 was CVI Holdings, an estimated $294K sold.
Based on aggregated 13F filings for Q2 2019.